Follow-up of patients with SVR Lawrence Serfaty Service d Hépatologie, UMR_S 938 Hôpital Saint-Antoine Université Pierre&Marie Curie Paris, France
|
|
- Laureen Perkins
- 6 years ago
- Views:
Transcription
1 9th Paris Hepatitis Conference, January 11-12, 2016 Follow-up of patients with SVR Lawrence Serfaty Service d Hépatologie, UMR_S 938 Hôpital Saint-Antoine Université Pierre&Marie Curie Paris, France
2 Disclosures Consulting, advisory committees or review panel Abbvie, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Janssen, Merck Sharp & Dohme, Roche Speaking and teaching Abbvie, Aptalis, Bristol-Myers Squibb, Gilead, Janssen, Merck Sharp & Dohme, Roche
3 New all-oral regimens are transforming the HCV treatment landscape BOC, boceprevir; IFN, interferon; RBV, ribavirin; SVR, sustained virologic response; TVR, telaprevir 1. Adapted from Manns MP, et al. Gut 2006;55: Tran TT. Am J Manag Care 2012;18(14 Suppl.):S Goralczyk AD, et al. BMC Gastroenterology 2013;13: Feld JJ, et al. N Engl J Med. 2014;370: Sulkowski M, et al. N Engl J Med. 2014;370(3): Afdhal N, et al. N Engl J Med. 2014;370: Afdhal N, et al. N Engl J Med. 2014;370: SVR (%) % 95 98%** 67 79%* 54 63% 38 43% 45 47% 31 35% 6% 13 19% IFN 24 wk IFN 48 wk IFN/RBV IFNα/RBV IFNα/RBV pifnα/rbv pifnα/rbv 3 DAAs 2 DAAs (daily) 3 times/wk 24 wk 48 wk 48 wk 48 wk + BOC or + ±RBV TVR RBV 12/24 wk wk 12 wk > and beyond patients with HCV genotype 1 only; ** In treatment-naïve patients; Includes treatment-naïve and -experienced patients
4 SVR is associated with improvement of survival (meta-analysis n= ) Effect of SVR on death (all cause) HCV 10 studies HCV cirrhosis 3 studies HIV/HCV 2 studies Risk reducton of death % Simmons B, et al. Clin Infec Dis 2015
5 Plan The durability of SVR with DAAs regimens Liver-related morbidity/mortality in SVR patients Long term fibrosis outcome in SVR patients Predictors of liver disease outcome in SVR patients: the role of comorbidities Monitoring of SVR patients: the value of non invasive markers
6 Plan The durability of SVR with DAAs regimens Liver-related morbidity/mortality in SVR patients Long term fibrosis outcome in SVR patients Predictors of liver disease outcome in SVR patients: the role of comorbidities Monitoring of SVR patients: the value of non invasive markers
7 The durabilty of SVR with DAAs regimens 779 patients treated with sofosbuvir-containing regimen Yoshida EM, et al. Hepatology 2015
8 The durabilty of SVR with DAAs regimens Long term follow-up studies in DAAs-related SVR patients are ongoing. Persitence of occult HCV infection? Radkowski M, et al. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology 2005; 41: Castillo I, et al. Hepatitis C virus replicates in the liver of sustained responder patients to Long term antiviral SVR treatment. and Clin Infect shorter Dis 2006; 43: duration regimen?
9 Risk of reinfection following SVR (meta-analysis n= ) 5 yrs risk of reinfecton post SVR 25 Low risk n = Mean FU 4.1 yrs IVDU/inmate n = Mean FU 5 yrs HIV/HCV n = Mean FU 3.1 yrs 23.6 EASL guidelines Following SVR, monitoring for HCV reinfection through annual HCV RNA assessment should be undertaken in people who inject drugs or men who have sex with men with on-going risk behaviour (B2) HCV reinfecton at 5 yrs (%) Low risk 8.2 IVDU/ inmate Coinfected Hill AM, et al. AASLD 2014
10 Plan The durability of SVR with DAAs regimens Liver-related morbidity/mortality in SVR patients Long term fibrosis outcome in SVR patients Predictors of liver disease outcome in SVR patients: the role of comorbidities Monitoring of SVR patients: the value of non invasive markers
11 The risk of liver transplantation or HCC according to SVR (meta-analysis n= ) % of patents afer 5 yrs Liver transplantaton risk at 5 yrs HCV n = 108 Mean FU 4.2 yrs HCV cirrhosis n = Mean FU 7.7 yrs 0.2 SVR 7.3 HIV/HCV n = Mean FU 4.9 yrs Non SVR HCV infected Cirrhosis HIV/HCV % of patents afer 5 yrs HCV n = Mean FU 6.1 yrs HCC risk at 5 yrs HCV cirrhosis n = 4987 Mean FU 6.6 yrs HIV/HCV n = Mean FU 4.7 yrs 10 HCV infected Cirrhosis HIV/HCV Simmons B, et al. Clin Infec Dis 2015
12 Excess liver-related morbidity following discharge of SVR patents 1215 HCV patients treated between , follow-up 5.3 yrs Adjusted standardized morbidity ratio (liver-related hospitalizations) Innes HA, et al. Hepatology 2011
13 Risk of HCC in non cirrhotic patients following HCV eradication 642 SVR patients followed 53 mo: 86 cirrhotics, 556 non-cirrhotics 22.6 % at 5 yrs 3.2 % at 5 yrs Huang CF, et al. J Hepatol 2014
14 Plan The durability of SVR with DAAs regimen Liver-related morbidity/mortality in SVR patients Long term fibrosis outcome in SVR patients Predictors of liver disease outcome in SVR patients: the role of comorbidities Monitoring of SVR patients: the value of non invasive markers
15 Regression of fibrosis in SVR patients is slow 183 HCV patients with SVR 2nd liver biopsy at 3.7 yrs Fibrosis stage on second LB Fibrosis stage on first LB Mean rate of fibrosis regression: 0.28±0.03 unit/yr Shiratori Y, et al. Ann Intern Med 2000
16 Tachi Y, et al. Hepatol Res 2015; 45: Regression of fibrosis in SVR patients is slow 97 SVR patients with paired LB, 5.8 yrs Improvement Stable Progression 6
17 Long term fibrosis outcomes in SVR patients according to non invasive markers 933 HCV patients with paired Fibrotest, median FU 5.3 yrs 415 patients with advanced fibrosis at 10 yrs atients at risk n= Poynard T, et al. J Hepatol 2013
18 Plan The durability of SVR with DAAs regimens Liver-related morbidity/mortality in SVR patients Long term fibrosis outcome in SVR patients Predictors of liver disease outcome in SVR patients: the role of comorbidities Monitoring of SVR patients: the value of non invasive markers
19 Wiese M, et al. Hepatology 2014 ;59: Overweight is a risk factor of cirrhosis occurrence in SVR patients German HCV (1b)-contaminated anti-d cohort: Clinical outcome after 35 yrs follow-up Overall survival was significantly enhanced after SVR, compared to treatment-naïve patients or non-svr (p=0.027) (%) Overall cohort Spontaneous Treatment recovery naïve SVR Non SVR Independent factors associated with cirrhosis No response to treatment No spontaneous recovery BMI >25 kg/m2 (RR: 1.125) Fibrosis F3 Cirrhosis Death
20 Risk factors of HCC following SVR SVR patients Follow-up (yrs) Risk factors Chang Age -Fibrosis -Post SVR AFP Arase Age -Male -Alcohol -Diabetes Oze Age -Post SVR AFP Yamashita Age -Fibrosis -Alcohol -Post SVR AFP Huang Age -Fibrosis -Diabetes Chang Age -Fibrosis Courtesy by P Nahon -Post SVR AFP 20
21 etabolic syndrome and risk of HCC n SVR cirrhotic patients Risk of HCC according to SVR and Met S CirVir CO12 ANRS CO12 CirVir EASL 2015
22 Risk factors of HCC following SVR in non cirrhotic patients 556 non-cirrhotic patients with SVR Predictive factors of HCC : age, GGT, type 2 diabetes and APRI Huang CF, et al. J Hepatol 2014
23 Predictive score of HCC occurrence in cirrhotic patients Independent predictors: Age>50yrs, Alcohol, GGT>N, platelets, SVR Score 5 : low risk; 6-10 : moderate risk; 11-14: high risk; > 14: very high risk CirVir CO12 P < CirVir ANRS CO12, AFEF/ILCA 2015
24 Progression of fibrosis is associated with HCC occurrence in SVR patients Tachi Y, et al.. Hepatol Res 2015; 45: SVR patients with paired LB, 5.8 yrs
25 Mallet L, et al. Ann Intern Med 2008;149: Reversion of cirrhosis and clinical outcome n=57 n=39 SVR n=78 n=18 Reversion CHC: 14 (23.3%) CHC: 17 (22.1%) CHC: 3 (7.7%) * CHC: 0
26 Plan The durability of SVR with DAAs regimens Liver-related morbidity/mortality in SVR patients Long term fibrosis outcome in SVR patients Predictors of liver disease outcome in SVR patients: the role of comorbidities Monitoring of SVR patients: the value of non invasive markers
27 Difference between biopsy and FibroTest estimates of fibrosis progression in treated patients 134 patients treated with IFN and 352 treated with IFN+RBV Poynard et al 2002, SVR Poynard et al 2003, SVR Poynard et al 2003, NR Poynard et al 2003, NR Total Mean difference Poynard T, et al. Antivir Ther 2010
28 Accuracy of APRI, FIB-4 and Forns index at post-svr for predicting fibrosis in the second liver biopsy 115 SVR patients with control liver biopsy at 5 yrs APRI FIB-4 Forns ROC>0.8 Accuracy>70% APRI FIB-4 Forns Tachi Y, et al. PloS One 2015
29 Accuracy of fibroscan following SVR 33 biopsy-proven cirrhotic CHC patients with SVR Liver biopsy + LSM 61 (48-104) months after SVR F0-3 F4 TE <12 kpa TE 12 kpa D Ambrosino R, et al. J Hepatol 2013
30 Liver stiffness and antiviral treatment: lower cut-off for cirrhosis diagnosis? Fibrosis Steatosis Inflammation Liver stiffness (kpa) F4 F4 Cirrhosis diagnosis Courtesy by J Boursier
31 Take-Home Message After the cure of HCV infection, regression of fibrosis varies and the risk of liver-related complications remains, even in the absence of cirrhosis. Comorbidities such as diabetes, obesity or alcohol consumption can play a major role in the outcome of liver disease in SVR patients and should be managed. Although not currently recommended in guidelines, noninvasive tests could be useful for assessing the outcome of fibrosis in SVR patients without cirrhosis. Screening for HCC after HCV cure is recommended in patients with extensive fibrosis.
32 Baseline F0/F1 F2/F3 Cirrhosis Antiviral tt SVR12 SVR12 SVR12 W48FU PCR NIT=F0/F1 PCR NIT=F2/F3 PCR Persistent risk factors IVDU, MMS Age>60, GGT Alcohol, obesity, diabetes PCR/yr NIT/yr Lifestyle change Control of diabetes LB if abnormal LFT US/6mo NIT: non invasive test
33
Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR
Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR This program is supported by educational grants from AbbVie, Gilead Sciences, and Merck About These Slides Please feel free to use,
More informationHCV care after cure. This program is supported by educational grants from
HCV care after cure This program is supported by educational grants from Raffaele Bruno,MD Department of Infectious Diseases, Hepatology Outpatients Unit University of Pavia Fondazione IRCCS Policlinico
More informationThe Changing World of Hepatitis C
The Changing World of Hepatitis C Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia St. Paul s Hospital Site Disclosures
More informationHepatitis C - results in real life
Hepatitis C - results in real life Robert Flisiak Department of Infectious Diseases and Hepatology Medical University of Białystok, Poland 10th PHC Paris, 30-31 January 2017 Disclosures Advisor and/or
More information3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice
3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice Rome, 13 December 2013 Management and monitoring of HCC in the future era of DAA s Prof. Massimo Colombo Chairman Department of Liver,
More informationMeet the Professor: HIV/HCV Coinfection
Meet the Professor: HIV/HCV Coinfection Vincent Lo Re, MD, MSCE Assistant Professor of Medicine and Epidemiology Division of Infectious Diseases Center for Clinical Epidemiology and Biostatistics University
More informationHepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany
Hepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany PHC 2018 - www.aphc.info Disclosures Advisory boards:
More informationHepatitis C 17 months experience with Sofosbuvir/Ledipasvir (Harvoni)
Hepatitis C 17 months experience with Sofosbuvir/Ledipasvir (Harvoni) Prof. Dr. Markus Cornberg Klinik für Gastroenterologie, Hepatologie und Endokrinologie Antalya, 13.05.2016 Markus Cornberg, Hannover
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC JORGE L. HERRERA, MD, MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE Worldwide Causes of HCC 60% 50% 40% 54% 30% 20% 10% 31% 15% 0% Hepatitis B Hepatitis
More informationThe Effect of Antiviral Therapy on Liver Fibrosis in CHC. Jidong Jia Beijing Friendship Hospital, Capital Medical University
The Effect of Antiviral Therapy on Liver Fibrosis in CHC Jidong Jia Beijing Friendship Hospital, Capital Medical University 2016-5-29 1 Disclosure Consultation for Abbvie, BMS, Gilead, MSD, Novartis and
More informationScreening for HCCwho,
Screening for HCCwho, how and how often? Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital HCC Global Epidemiology
More informationAbstract and Introduction. Patients and Methods. M. Hedenstierna; A. Nangarhari; A. El-Sabini; O. Weiland; S.
www.medscape.com Cirrhosis, High Age and High Body Mass Index Are Risk Factors for Persisting Advanced Fibrosis After Sustained Virological Response in Chronic Hepatitis C M. Hedenstierna; A. Nangarhari;
More informationTHE THERAPEUTIC REVOLUTION THAT TRANSFORMED CHRONIC HEPATITIS C TO A CURABLE DISEASE
THE THERAPEUTIC REVOLUTION THAT TRANSFORMED CHRONIC HEPATITIS C TO A CURABLE DISEASE MARIA SCHINA CONSULTANT PHYSICIAN INTERNAL MEDICINE AND HEPATOLOGY ATHENS EUROCLINIC 10 th INTERNATIONAL CONGRESS OF
More informationHCV Case Study. Treat Now or Wait for New Therapies
HCV Case Study Treat Now or Wait for New Therapies This program is supported by educational grants from Kadmon and Merck Pharmaceuticals. Program Disclosure This activity has been planned and implemented
More informationThe Impact of HBV Therapy on Fibrosis and Cirrhosis
The Impact of HBV Therapy on Fibrosis and Cirrhosis Jordan J. Feld, MD, MPH Associate Professor of Medicine University of Toronto Hepatologist Toronto Centre for Liver Disease Sandra Rotman Centre for
More informationTransient elastography the state of the art
Transient elastography the state of the art Laurent CASTERA, MD PhD Department of Hepatology, Hôpital Beaujon, Clichy Université Paris-7, France White Nights of Hepatology, St Petersburg, Russia, june
More informationHow do you optimize HCV Treatment for Cirrhotic Patients APASL STC Cebu
How do you optimize HCV Treatment for Cirrhotic Patients APASL STC Cebu Seng Gee Lim Chairman, APASL Liver Week 2013 Professor of Medicine Dept of Gastroenterology and Hepatology NUHS, Singapore Disclosures
More informationClinical Cases Hepatitis C Naïve Patients. Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona.
Clinical Cases Hepatitis C Naïve Patients Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona. Case study 1 27 year old woman, Diagnosed with Chronic Hepatitis C 3 years ago
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC Mark W. Russo, MD, MPH, FACG Carolinas HealthCare System Charlotte Worldwide Causes of HCC 60% 50% 40% 30% 20% 10% 0% 54% 31% 15% Hepatitis B Hepatitis C
More informationAASLD, Boston, USA, 10 th November 2014 [oral presentation]
Effects of Sustained Virological Response on the of liver transplant, hepatocellular carcinoma, death and re-infection: meta-analysis of 129 studies in 34,563 patients with Hepatitis C infection. Andrew
More informationRome, February nd Riunione Annuale AISF th AISF ANNUAL MEETING
Rome, February 20-21 nd 2014 Riunione Annuale AISF 2014 14 th AISF ANNUAL MEETING Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations IFN
More informationWhy make this statement?
HCV Council 2014 10 clinical practice statements were evaluated by the Council A review of the available literature was conducted The level of support and level of evidence for the statements were discussed
More informationThe impact of the treatment of HCV in developing Hepatocellular Carcinoma
The impact of the treatment of HCV in developing Hepatocellular Carcinoma Paul Y Kwo, MD Professor of Medicine Medical Director, Liver Transplantation Gastroenterology/Hepatology Division Indiana University
More informationAntiviral treatment in HCV cirrhotic patients on waiting list
Antiviral treatment in HCV cirrhotic patients on waiting list Krzysztof Tomasiewicz Department of Hepatology and Infectious Diseases Medical University of Lublin, Poland Disclosures Consultancy/Advisory
More informationHow to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France
How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France Paris Hepatitis Conference, January 12, 2016 Disclosures I have received funding
More informationLatest Treatment Updates for GT 2 and GT 3 Patients
Latest Treatment Updates for GT 2 and GT 3 Patients Eric Lawitz, MD, AGAF, CPI Vice President, Scientific and Research Development The Texas Liver Institute Clinical Professor of Medicine University of
More informationHepatitis C: a treatment revolution
Sunday, 10th July 2016 Michaelmas Cay 2 Room Concurrent 11 Health Innovation Hepatitis C: a treatment revolution Dr. Heather McNamee Hepatitis C a treatment revolution Dr Heather McNamee Medical Director
More informationShould Elderly CHC Patients (>70 years old) be Treated?
Should Elderly CHC Patients (>70 years old) be Treated? Deepak Amarapurkar Consultant Gastroenterologist & Hepatologist Bombay Hospital & Medical Research Center, Mumbai & Jagjivanram Western Railway Hospital,
More informationIFN-free therapy in naïve HCV GT1 patients
IFN-free therapy in naïve HCV GT1 patients Paris Hepatitis Conference Paris, 12th January, 2015 Pr Tarik Asselah MD, PhD; Service d Hépatologie & INSERM U773 University Paris Diderot, Hôpital Beaujon,
More informationCurrent trends in CHC 1st genotype treatment
Current trends in CHC 1st genotype treatment Tarik Asselah MD, PhD Professor of Medicine Hepatology, Chief INSERM UMR 1149, Hôpital Beaujon, Clichy, France Disclosures Employee of Paris Public University
More information47 th Annual Meeting AISF
47 th Annual Meeting AISF Rome, 21 February 2014 Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations (HCV/HIV coinfection, advanced cirrhosis,
More informationHepatitis C and HIV. Stanislas Pol
Hepatitis C and HIV Stanislas Pol Unité d Hépatologie, Hôpital Cochin Inserm U1223 & USM20 Institut Pasteur Université Paris Descartes Paris, France stanislas.pol@cch.aphp.fr Lisboa, 30 January 2017 Disclosures
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationDAA-based treatment in cirrhotic and post-transplanted patients. Audrey Coilly, MD Hôpital Paul Brousse, Villejuif, France
DAA-based treatment in cirrhotic and post-transplanted patients Audrey Coilly, MD Hôpital Paul Brousse, Villejuif, France Cirrhosis and transplantation 2 populations with similar issues Hepatic impairment
More informationLa gestione corrente dell infezione cronica da HCV: la progressione verso la cirrosi. Simona Landonio I Div Mal inf H Sacco Milano
La gestione corrente dell infezione cronica da HCV: la progressione verso la cirrosi Simona Landonio I Div Mal inf H Sacco Milano HCV Natural History Viganò M et al Gastroenterology 27;133:835-842 Overall
More informationLiver transplantation and hepatitis C virus
Liver transplantation and hepatitis C virus Where do we come from? Where are we? Where are we going? François Durand Hépatologie & Réanimation Hépato-Digestive INSERM U1149 Hôpital Beaujon, Clichy HCV:
More informationInvasive. Sampling error. Interobserver variability. Nondynamic evaluation of
How to assess liver fibrosis Serum markers or FibroScan vs. liver biopsy? Laurent CASTERA & Pierre BEDOSSA Hôpital Beaujon, AP-HP, Clichy Université Paris-VII France 4 th Paris Hepatitis Conference, Paris,
More informationAccepted Manuscript. Hepatitis C virus infection, a new modifiable cardiovascular risk factor. Patrice Cacoub
Accepted Manuscript Hepatitis C virus infection, a new modifiable cardiovascular risk factor Patrice Cacoub PII: S0016-5085(19)30382-8 DOI: https://doi.org/10.1053/j.gastro.2019.02.009 Reference: YGAST
More informationManagement of HCV in Decompensated Liver Disease
Management of HCV in Decompensated Liver Disease Michael P. Manns Hannover Medical School (MHH) Department of Gastroenterology, Hepatology and Endocrinology Helmholtz Center for Infection Research (HZI),
More informationTreatment of HCV infection in daily clinical practice. Which are the optimal options for Genotypes 2 and 3? Jiannis Vlachogiannakos
Treatment of HCV infection in daily clinical practice. Which are the optimal options for Genotypes 2 and 3? Jiannis Vlachogiannakos Associate Professor of Gastroenterology Academic Department of Gastroenterology
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Clinical Criteria for Hepatitis C (HCV) Therapy Pre-Treatment Evaluation o Must have chronic hepatitis C and HCV genotype and sub-genotype documented; o Patients who have prior exposure to DAA therapy
More informationHepatitis C in Disclosures
Hepatitis C in 2018 Sandeep Mukherjee, MD CHI Health and Creighton University Medical Center Division of Gastroenterology Grant support: Abbvie Disclosures Speaker: Abbvie, Gilead, Merck Section editor
More informationANTIVIRAL THERAPY FOR HCV. Alfredo Alberti
CLINICAL IMPACT OF SVR AFTER ANTIVIRAL THERAPY FOR HCV Alfredo Alberti Department of Histology,Microbiology and Medical Biotechnologies Molecular Hepatology Unit Venetian Institute of Molecular Medicine
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationSHOULD EVERYONE WITH HCV/HIV COINFECTION BE TREATED NOW?
SHOULD EVERYONE WITH HCV/HIV COINFECTION BE TREATED NOW? Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Disclosures
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Clinical Criteria for Hepatitis C (HCV) Therapy Pre-Treatment Evaluation o Must have chronic hepatitis C and HCV genotype and sub-genotype documented; o Patients who have prior exposure to DAA therapy
More informationHCV In 2015: Maximizing SVR
HCV In 2015: Maximizing SVR Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia ramji_a@hotmail.com Disclosures (within Last
More informationTREATMENT OF GENOTYPE 2
Treatment of Genotype 2, 3,and 4 David E. Bernstein, MD, FACG Advisory Committee/Board Member: AbbVie Pharmaceuticals, Gilead, Merck, Janssen Consultant: AbbVie Pharmaceuticals, Bristol-Myers Squibb, Gilead,
More informationCan we afford to Cure all HIV-HCV Co-infected Patients of HCV?
Can we afford to Cure all HIV-HCV Co-infected Patients of HCV? Michael S. Saag, MD Professor of Medicine University of Alabama at Birmingham Birmingham, Alabama FINAL AU EDITED: 09-17-14 Disclosure Dr
More informationUpdate in hepatitis C virus infection
Update in hepatitis C virus infection Eoin Feeney Consultant in Infectious Diseases St. Vincent s University Hospital Overview Natural history Diagnosis, screening, staging Management Barriers going forward
More informationTough Cases in HIV/HCV Coinfection
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Tough Cases in HIV/HCV Coinfection John Scott, MD, MSc Assistant Professor University of Washington Presentation prepared by: J Scott Last Updated: Jun 5, 2014
More informationHepatitis C Management and Treatment
Hepatitis C Management and Treatment Kaya Süer Near East University Faculty of Medicine Infectious Diseases and Clinical Microbiology 1 Discovery of Hepatitis C Key facts Hepatitis C: the virus can cause
More informationHEPATITIS B: WHO AND WHEN TO TREAT?
HEPATITIS B: WHO AND WHEN TO TREAT? George V. Papatheodoridis Professor in Medicine & Gastroenterology Medical School of National & Kapodistrian University of Athens Director of Academic Department of
More informationHCV therapy : Clinical case
HCV therapy : Clinical case PHC 2018 Paris January 14th, 2018 Tarik Asselah (MD, PhD) Professor of Medicine Hepatology, Chief INSERM UMR 1149, Hôpital Beaujon, Clichy, France. Disclosures Professor Asselah
More informationHCV eradication with direct acting antivirals (DAAs)? Why is viral cure possible in HCV? Emilie Estrabaud
HCV eradication with direct acting antivirals (DAAs)? Why is viral cure possible in HCV? Emilie Estrabaud Service d Hépatologie et INSERM UMR1149, AP-HP Hôpital Beaujon, Paris, France. emilie.estrabaud@inserm.fr
More informationChronic viral hepatitis and liver disease in Belgium Pierre Deltenre
Chronic viral hepatitis and liver disease in Belgium Pierre Deltenre Brussels, November 7, 2017 Hepatitis B and C in Belgium What we need to know 1. Who is at risk of infection? 2. What is the natural
More informationSpecial developments in the management of Hepatitis C. Disclosures
Special developments in the management of Hepatitis C Sandeep Mukherjee,MD Division of Gastroenterology CHI Health and Creighton University Medical Center Omaha, NE 68154 Sandeep.Mukherjee@alegent.org
More informationEmerging Challenges In Primary Care: 2015
Care Se'ng Emerging Challenges In Primary Care: 2015 Chronic Hepatitis C: Update on Screening, Diagnosis, Management, and Promising New Treatments 1 Faculty Kalyan R. Bhamidimarri, MD, MPH Assistant Professor
More informationDisclosures 29/09/2014. Genetic determinants of. HCV treatment outcome. IDEAL: IL28B-type is the strongest pre-treatment predictor of SVR
29/9/214 Genetic determinants of ᴧ HCV treatment outcome Disclosures Advisory board member - Gilead, Abbvie, Bristol-Myers Squibb (BMS), Janssen, Merck, and oche Speaker - Gilead, Janssen, Merck, BMS,
More informationPatients with compensated cirrhosis: how to treat and follow-up
Patients with compensated cirrhosis: how to treat and follow-up Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Universitätsklinikum Leipzig Leber- und Studienzentrum
More informationEmerging Challenges In Primary Care: 2015
Care Se'ng Emerging Challenges In Primary Care: 2015 Chronic Hepatitis C: Update on Screening, Diagnosis, Management, and Promising New 1 Faculty Kalyan R. Bhamidimarri, MD, MPH Assistant Professor of
More informationHIV-HCV coinfection. Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Baltimore, Maryland
HIV-HCV coinfection Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Baltimore, Maryland Disclosures Principal investigator for research grants Funds paid to Johns Hopkins
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Clinical Criteria for Hepatitis C (HCV) Therapy Pre-Treatment Evaluation o Must have chronic hepatitis C and HCV genotype and sub-genotype documented; o Patients who have prior exposure to DAA therapy
More informationProfessor Mark Nelson. Chelsea and Westminster Hospital, London, UK
Professor Mark Nelson Chelsea and Westminster Hospital, London, UK Treatment should be prioritized Treatment Indicated All naive and experienced pts with liver disease Prioritized Pts with fibrosis (F3)
More informationProgram Disclosure. Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.5 contact hours.
Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint-sponsorship
More informationHCV Treatment in 2016: is there still a role for IFNa and ribavirin?
HCV Treatment in 2016: is there still a role for IFNa and ribavirin? Heiner Wedemeyer Hannover Medical School Germany 1 Disclosures Honoraria for consulting or speaking (last 5 years): Abbott, AbbVie,
More informationUtility of Virological Assays at the DAA Era
Utility of Virological Assays at the DAA Era Prof. Jean-Michel Pawlotsky, MD, PhD National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital
More informationHCV: Racial Disparities. Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD
HCV: Racial Disparities Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD Charles Howell Disclosures Research Grants Boehringer Ingelheim, Inc.
More informationTreatment of chronic hepatitis delta Case report
Treatment of chronic hepatitis delta Case report George Papatheodoridis Professor in Medicine & Gastroenterology Medical School of National and Kapodistrian University of Athens, Director of Academic Department
More informationDelta hepatitis: How to manage and optimize therapy? Dominique ROULOT Unité d Hépatologie, Hôpital Avicenne
Delta hepatitis: How to manage and optimize therapy? Dominique ROULOT Unité d Hépatologie, Hôpital Avicenne Delta hepatitis treatment in 2018 Currently, Peg-IFNα 180 µg/wk is the only effective treatment
More informationCurrent Treatment Options for HCV Patients. Michael Manns Dept. of Gastroenterology, Hepatology and Endocrinology Hannover Germany
Current Treatment Options for HCV Patients Michael Manns Dept. of Gastroenterology, Hepatology and Endocrinology Hannover Germany 7th International Congress of Internal Medicine of Central Greece, Larissa,
More informationUpdate on chronic hepatitis C treatment: current trends, new challenges, what next?
Update on chronic hepatitis C treatment: current trends, new challenges, what next? Matti Maimets 12.06.2015 MMaimets15 Disclosure this presentation is sponsored by Gilead Sciences MMaimets15 MMaimets15
More informationPopulation Viral Kinetic Modeling: SVR Prediction in HCV GT-3 Cirrhotic Patients With 24 Weeks of Daclatasvir + Sofosbuvir Administration
Population Viral Kinetic Modeling: SVR Prediction in HCV GT-3 Cirrhotic Patients With 24 Weeks of Daclatasvir + Sofosbuvir Administration Emi Tafoya, Yasong Lu, Melody Luo, Premkumar Narasimhan, Neelima
More informationFuture strategies with new DAAs
Future strategies with new DAAs Ola Weiland professor New direct antiviral drugs Case no 1 male with genotype 2b Male with gt 2b chronic HCV Male with gt 2b relapse afer peg-ifn + RBV during 24 weeks
More informationThe Impact of DAA on HCC Occurrence
The Impact of DAA on HCC Occurrence Professeur Didier Samuel Centre Hépatobiliaire Inserm-Paris Sud Research Unit 1193 Departement Hospitalo Universitaire Hepatinov Hôpital Paul Brousse Université Paris
More informationHEPATITIS C: UPDATE AND MANAGEMENT
HEPATITIS C: UPDATE AND MANAGEMENT José Franco, MD Professor of Medicine Associate Dean for Educational Improvement Associate Director, Kern Institute STAR Center Director José Franco, MD Disclosures I
More informationHepatitis C Virus (HCV) & Infectious Disease 101 for Hubs & Spokes April 24, :00 pm 1:00 pm
Hepatitis C Virus (HCV) & Infectious Disease 101 for Hubs & Spokes April 24, 2018 12:00 pm 1:00 pm Presenters: Thomas E. Freese, PhD, Larissa Mooney, MD, & Rachel McLean, MPH, Chief, Office of Viral Hepatitis
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline Name Olysio (simeprevir) Formulary UnitedHealthcare Community & State Formulary Note Approval Date 2/19/2014 Revision Date 7/9/2014 1. Indications Drug Name: Olysio
More information6/2/2015. Interactive Case-Based Presentations and Audience Discussion
6/2/215 Interactive Case-Based Presentations and Audience Discussion Andrew Aronsohn, MD Assistant Professor of Medicine University of Chicago Medical Center Chicago, Illinois Formatted:5-6-215 Washington,
More informationDr. Siddharth Srivastava
Dr. Siddharth Srivastava MD, DM (Gastroenterology) Associate Professor GIPMER, New Delhi Rashtriya Gaurav Award 2013 for work on hepatitis B and C Set up Liver clinic at GIPMER and in charge EUS laboratory.
More informationHEPATITIS C UPDATES. Sanaa S. Said 10 th April, 2014
HEPATITIS C UPDATES Sanaa S. Said 10 th April, 2014 CONTENTS Introduction Epidemiology Transmission and Natural history Kenyan guidelines What is new? References INTRODUCTION Hepacivirus genus, Flaviviridae
More informationProtease inhibitor based triple therapy in treatment experienced patients
Protease inhibitor based triple therapy in treatment experienced patients Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber
More informationMOSCOW CLINICAL SCIENTIFIC CENTER
MOSCOW CLINICAL SCIENTIFIC CENTER Efficacy and safety of Narlaprevir in Russian population of patients with HCV-infection genotype 1: the final results of multicenter randomized placebo-controlled double-blind
More informationApproved regimens for cirrhotic patients
5th Workshop on HCV THERAPY ADVANCES New antivirals in clinical practice Approved regimens for cirrhotic patients Amsterdam, 4-5 december 2015 Disease burden in Spain 400000 350000 300000 F0 Peak cirrhosis
More informationHow to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy
How to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More informationAntiviral agents in HCV
Antiviral agents in HCV : Upcoming Therapeutic Options Su Jong Yu, M.D., Ph.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Estimated 170 Million
More informationHCV elimination : lessons from Scotland
HCV elimination : lessons from Scotland Sharon Hutchinson Glasgow Caledonian University / Health Protection Scotland BHIVA Hepatology Highlights, Edinburgh, 17 th April 2018 Disclosures Honoraria from
More informationWill difficult-to-treat patients remain difficultto-treat. generation of treatments?
Will difficult-to-treat patients remain difficultto-treat with the new generation of treatments? Jordan J Feld MD MPH Toronto Centre for Liver Disease Sandra Rotman Centre for Global Health University
More informationHepatitis C Introduction and Overview
Hepatitis C Introduction and Overview Michael S. Saag, MD Professor of Medicine Associate Dean of Global Health Director, Center for AIDS Research University of Alabama at Birmingham Birmingham, Alabama
More informationASSESSMENT PRIOR TO TREATMENT DO WE NEED IL28B TESTING?
ASSESSMENT PRIOR TO TREATMENT DO WE NEED IL28B TESTING? DO WE NEED LIVER BIOPSY? Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA POTENTIAL
More informationWe don t need a liver biopsy. We have non-invasive tests
We don t need a liver biopsy We have non-invasive tests Laurent CASTERA, MD PhD Department of Hepatology, Hôpital Beaujon, Clichy Université Paris Diderot, France PHC 2018 www.aphc.info Liver biopsy: an
More information4/30/2015. Interactive Case-Based Presentations and Audience Discussion. Debika Bhattacharya, MD, MSc. Learning Objectives
4/3/215 Interactive Case-Based Presentations and Audience Discussion Debika Bhattacharya, MD, MSc Assistant Clinical Professor University of California Los Angeles Los Angeles, California Formatted:4-27-215
More informationCURRENT TREATMENTS. Mitchell L Shiffman, MD Director Liver Institute of Virginia. Richmond and Newport News, VA, USA
CURRENT TREATMENTS FOR HCV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA, USA Liver Institute of Virginia Education, Research and
More informationHepatocellular Carcinoma: Can We Slow the Rising Incidence?
Hepatocellular Carcinoma: Can We Slow the Rising Incidence? K.Rajender Reddy M.D. Professor of Medicine Director of Hepatology Medical Director of Liver Transplantation University of Pennsylvania Outline
More informationHepatitis C Resistance Associated Variants (RAVs)
Hepatitis C Resistance Associated Variants (RAVs) Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Nothing to disclose Disclosure
More informationTreatment of Chronic Hepatitis C in HIV infection
Treatment of Chronic Hepatitis C in HIV infection June 25, 211 Andrew Talal, MD, MPH Associate Professor of Medicine Associate Medical Director Center for the Study of Hepatitis C Weill Cornell Medical
More informationOral combination therapy: future hepatitis C virus treatment? "Lancet Oct 30;376(9751): Oral combination therapy with a nucleoside
Author manuscript, published in "Journal of Hepatology 2011;55(4):933-5" DOI : 10.1016/j.jhep.2011.04.018 Oral combination therapy: future hepatitis C virus treatment? Commentary article on the following
More informationClinical Сase A previously relapse to PEG IFN + RBV in HCV G3a patient. Konstantin Zhdanov
Clinical Сase A previously relapse to PEG IFN + RBV in HCV G3a patient Konstantin Zhdanov Genotype 3 in Europe Canada Norway Germany Sweden Czech Republic Poland Approximately 1/3 of HCV-infected patients
More informationManagement of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy?
Management of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy? Prof. Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of
More informationAssociate Professor of Medicine University of Chicago
Nancy Reau, MD Associate Professor of Medicine University of Chicago Management of Hepatitis C: New Drugs and New Paradigms HCV is More Lethal than HIV Infection HCV superseded HIV as a cause of death
More information